Credit Suisse Upgrades Satsuma Pharmaceuticals (STSA) to Neutral

March 2, 2021 4:45 AM EST
Get Alerts STSA Hot Sheet
Price: $5.03 -4.19%

Rating Summary:
    0 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

Credit Suisse analyst Evan Seigerman upgraded Satsuma Pharmaceuticals (NASDAQ: STSA) from Underperform to Neutral with a price target of $6.50 (from $3.50).

For an analyst ratings summary and ratings history on Satsuma Pharmaceuticals click here. For more ratings news on Satsuma Pharmaceuticals click here.

Shares of Satsuma Pharmaceuticals closed at $6.51 yesterday.

You May Also Be Interested In

Related Categories

Analyst PT Change, Hot Upgrades, Upgrades